Cytogenetic abnormalities and associated efficacy from a phase III study comparing alemtuzumab vs. chlorambucilas first line therapy for B-cell chronic lymphocytic leukemia

被引：0
|
作者：
Robak, T.
Skotnicki, A.
Dmoszynska, A.
Hebert, J.
Wang, Y.
Belkaci, M.
Sirard, C.
Mayer, J.
Hillmen, P.
机构：
[1] Kopernik Mem Hosp, Lodz, Poland
[2] Jagiellonian Univ, Coll Med, Krakow, Poland
[3] Clin Hosp No 1, Lublin, Poland
[4] Cirion BioPharma Res Inc, Laval, PQ, Canada
[5] Genzyme, Cambridge, MA USA
[6] Univ Hosp Brno, Brno, Czech Republic
[7] Leeds Gen Infirm, Leeds, W Yorkshire, England
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0128
引用
收藏
页码：46 / 46
页数：1
相关论文
共 50 条
  • [1] Incidence of genomic aberrations and associated efficacy from a phase III study comparing alemtuzumab (CAMPATH®, MABCAMPATH®) vs chlorambucil as first line therapy for B-cell chronic lymphocytic leukemia (BCLL).
    Robak, Tadeusz
    Dmoszynska, Anna
    Fetni, Raouf
    Wang, Ying
    Belkacz, Malika
    Sirard, Cynthia
    Goldberg, Mark
    Skotnicki, Aleksander
    Mayer, Jiri
    Hillmen, Peter
    BLOOD, 2006, 108 (11) : 593A - 593A
  • [2] Impact of prognostic factors on outcome in a phase III study comparing alemtuzumab to chlorambucil as first-line therapy for B-cell chronic lymphocytic leukemia (BCLL)
    Mayer, J.
    Robak, T.
    Skotnicki, A.
    Jaksic, B.
    Dmoszynska, A.
    Sirard, C.
    Hillmen, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Preliminary phase III efficacy and safety of alemtuzumab vs chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL).
    Hillmen, P.
    Skotnicki, A.
    Robak, T.
    Jaksic, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 339S - 339S
  • [4] Phase III study to evaluate the efficacy and safety of front-line therapy with alemtuzumab (CAMPATH®, MABCAMPATH®) vs. chlorambucil in patients with progressive B-cell chronic lymphocytic leukemia (CAM307).
    Skotnicki, AB
    Robak, T
    Mayer, J
    Craig, A
    Weitman, S
    BLOOD, 2003, 102 (11) : 439A - 439A
  • [5] Cytogenetic correlation with efficacy on alemtuzumab (CAM) vs chlorambucil (CHLO) as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL).
    Dmoszynska, A.
    Fetni, R.
    Wang, Y.
    Belkaci, M.
    Sirard, C.
    Goldberg, M.
    Mayer, J.
    Robak, T.
    Skotnicki, A.
    Hillmen, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 361S - 361S
  • [6] Interim safety summary of alemtuzumab vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL).
    Robak, T
    Skotnicki, AB
    Mayer, J
    Vukovic, V
    Weitman, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 573S - 573S
  • [7] Progression free survival is superior with alemtuzumab vs chlorambucil as front-line therapy for patients with B-cell chronic lymphocytic leukemia
    Hillmen, P.
    Skotnicki, A.
    Robak, T.
    Jaksic, B.
    Sirard, C.
    Mayer, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 45 - 46
  • [8] The relationship between oxidative stress and cytogenetic abnormalities in B-cell chronic lymphocytic leukemia
    Zhevak, Tatiana
    Shelekhova, Tatiana
    Chesnokova, Nina
    Tsareva, Olga
    Chanturidze, Anna
    Litvitsky, Petr
    Andriutsa, Natalia
    Samburova, Natalia
    Budnik, Ivan
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2020, 116
  • [9] Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories
    Fiegl, M.
    Erdel, M.
    Tinhofer, I.
    Brychtova, Y.
    Panovska, A.
    Doubek, M.
    Eigenberger, K.
    Fonatsch, C.
    Hopfinger, G.
    Muehlberger, H.
    Zabernigg, A.
    Falkner, F.
    Gastl, G.
    Mayer, J.
    Greil, R.
    ANNALS OF ONCOLOGY, 2010, 21 (12) : 2410 - 2419
  • [10] Clinical Outcome of B-Cell Chronic Lymphocytic Leukemia Following Alemtuzumab Therapy: Retrospective Study within Various Cytogenetic Risk Categories
    Fiegl, Michael
    Erdel, Martin
    Tinhofer, Inge
    Hopfinger, Georg
    Eigenberger, Karin
    Falkner, Florian
    Falkner, Andreas
    Brychtova, Yvona
    Panovska, Anna
    Doubek, Michael
    Zabernigg, August
    Sodia, Sigrun
    Muehlberger, Helmut
    Gastl, Guenther
    Mayer, Jiri
    Greil, Richard
    BLOOD, 2008, 112 (11) : 1085 - 1085
12345